Generation and characterization of lymphokine-activated killer cells from non-Hodgkin's lymphoma patients.
Lymphokine-activated killer cells generated from peripheral blood of Non-Hodgkin's lymphoma patients showed comparable levels of cytotoxicity. The patients with advanced disseminated disease displayed better augmentation with recombinant interleukin-2 (rIL-2) than the patients with localized disease. Thus, the defective cytotoxic potential of patients could be corrected in a culture of effector cells with IL-2. The indigenous ability to produce IL-2 in response to activation of peripheral blood mononuclear cells with phytohemagglutin showed slight depression and a positive correlation with the stage of the disease. Phenotypic analysis revealed a heterogenous population of cells involved in cytotoxic activity. Thus, IL-2 merits further evaluation in malignant lymphomas, particularly in relation to other variable therapies in conjunction with chemotherapy.
Jhaver
K G
KG
Immunology Division, Cancer Research Institute, Parel, Bombay, India.
Advani
S H
SH
Nadkarni
J J
JJ
D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D008213:Lymphocyte Activation; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000473:pathology*; D010641:Phenotype; D011994:Recombinant Proteins / Q000494:pharmacology
D000945:Antigens, Differentiation, T-Lymphocyte; D000951:Antigens, Neoplasm; D007376:Interleukin-2; D011994:Recombinant Proteins